Biopharma · FDA Approvals · Stock
BOLD Boundless Bio
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass pla…
Assets on file: BBI-940
Catalyst calendar
Dated catalysts for BOLD, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for BOLD, newest first.
BOLDBoundless Bio, Inc.Boundless Bio: FDA accepts IND for BBI-940 Kinesin degrader
The FDA accepted the IND for BBI-940 in January 2026, enabling the KOMODO-1 first-in-human trial to open for enrollment in ER+/HER2- and TNBC-LAR breast cancer. The company now has an active clinical program with cash runway into H2 2028 covering the expected initial proof-of-concept readout.
Peers by market cap
Companies in the same sector closest to BOLD in market value.
ONCYOncolytics BiotechMarket cap $55.8M · 1 tracked drug · 3 upcoming catalysts
VRCAVerrica PharmaceuticalsMarket cap $57.5M · 1 tracked drug · 3 upcoming catalysts
RNTXRein TherapeuticsMarket cap $57.8M · 1 tracked drug · 1 upcoming catalyst
CLNNCleneMarket cap $54.4M · 1 tracked drug · 1 upcoming catalyst
LFSLeifrasMarket cap $54.4M · 1 tracked drug
OSTXOS TherapiesMarket cap $58.0M · 1 tracked drug
XLOXilio TherapeuticsMarket cap $52.8M · 1 tracked drug · 1 upcoming catalyst
HRTXHeron TherapeuticsMarket cap $52.7M · 1 tracked drug